

+

PTO/SB/08A (08-00)

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	09/932,451
				Filing Date	August 17, 2001
				First Named Inventor	Ozawa et al.
				Group Art Unit	1635
				Examiner Name	B. Whiteman
Sheet	1	of	2	Attorney Docket Number	0800-0026

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
B2	B1		WO 00/38518 A		Leiden et al.	07/06/00	
	B2		WO 97/32990		Geary et al.	09/12/97	
	B3		WO 97/12050		Kaplitt	04/03/97	
PL	B4		EP 1 016 726 A1		Introgen Inc.	07/05/00	

Examiner Signature	<i>P. R. [Signature]</i>	Date Considered	8/16/04
-----------------------	--------------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Application Number	09/932,451
Filing Date	August 17, 2001
First Named Inventor	Ozawa et al.
Group Art Unit	1635
Examiner Name	B. Whiteman
Attorney Docket Number	0800-0026

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
PL	C1	Fisher, K.J. et al., "RECOMBINANT ADENO-ASSOCIATED VIRUS FOR MUSCLE DIRECTED GENE THERAPY", <i>Nature Medicine</i> , 3(3):306-312 (1997)
	C2	Gowdak L.H.W. et al., "INDUCTION OF ANGIOGENESIS BY CATIONIC LIPID-MEDIATED VEGF ₁₆₅ GENE TRANSFER IN THE RABBIT ISCHEMIC HINDLIMB MODEL", <i>Journal of Vascular Surgery</i> , 32(2):343-352 (2000)
	C3	Shimpo et al., "AAV-MEDIATED VEGF GENE TRANSFER INTO SKELETAL MUSCLE STIMULATES ANGIOGENESIS AND IMPROVES BLOOD FLOW IN A RAT HINDLIMB ISCHEMIA MODEL", <i>Cardiovascular Research</i> , 53(4):993-1001 (2002)
PN	C4	Su et al., "ADENO-ASSOCIATED VIRAL VECTOR-MEDIATED VASCULAR ENDOTHELIAL GROWTH FACTOR GENE TRANSFER INDUCES NEOVASCULAR FORMATION IN ISCHEMIC HEART", <i>PNAS</i> , 97(25):13801-13806 (2000)

Date Considered	8/16/04
-----------------	---------

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.